Search
Valine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalValine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Mixtures: TRAVASOL® SOLUCION BAL 8.5% SIN ELECTROLITOS, EAS ORAL 100 TABLETTeprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigational[L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAtobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. … Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form.
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … [L9338,L9356] It was also approved by the European Commission on August 17, 2022.[L43997] Traditionally, the triptan class of anti-migraine medications (e.g.
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding … [L56193,L56194] The application received priority review, breakthrough therapy designation, and orphan drug designation, and was reviewed under Project Orbis with the EMA as an official observer.
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationaltreatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Sorbitol
go.drugbank.com/drugs/DB01638ApprovedInvestigationalIt was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures.
Ozenoxacin
go.drugbank.com/drugs/DB12924ApprovedTo date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age
Fluticasone propionate
go.drugbank.com/drugs/DB00588ApprovedInvestigationalThese drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Products: Flonase - Aem-sus Nas 50mcg/mdSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … [L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR).